Translate
Thursday, 4 March 2021
MID DAY MEAL: A GAME CHANGER
Monday, 15 February 2021
VIRUS: The Facts
Understanding the Virosphere
Millions of years of evolution has caused
spectacular changes in our life,but what
remains a constant is the occurrence of diseases and viruses cause most of
them. In 1857 a strange contagious disease affecting up to 80 percent of the
tobacco crops. In 1879 plant pathologist Adolf Mayer named it the “ Mosaic
disease of tobacco”
In 1889 Dutch microbiologist Martinus W Beijerinck’s findings say the disease agent needed growing leaves to multiply or to infect other plants when he checked newly infected leaves,he found that with fresh infections the disease agent did not lose its disease- causing power.His conclusion was:the agent could grow on leaves but could not reproduce without them. He named this agent “Contagious vivum fluidum” or contagious living fluid. He also gave it a nickname,Viruses. Thus tobacco mosaic became the first virus to be discovered.
The world of viruses is dense and vast. Its
diversity is greater than the world that we know and interect in. Viruses are
omnipresent,found in air,land,sea to every species to even in every body parts.
Virus disrupts cell function in its desperation to replicate. This makes us
sick. In response to infection the immune system springs into action white
blood cells,antibodies and other mechanisms go on an overdrive to rid the body
of the foreign invader. These cause fever,rash,headach and fatigue.
A disease occurs when the immune system loses ground to the viruses and
the later manages to establish itself in the cells for replication. The
replication process typically begins when a virus infects its host by attaching
to the host cell and penetrating the cell wall or membrane.
The virus genome is then uncoated
from the protein and hijacks the host cell’s machinery,forcing it to replicate
the viral genome and produce viral proteins to make new capsids. The new
viruses then burst out of the host cell during a process called lysis,which
kills the host cell. Some viruses take a portion of the host’s membrane during
the lysis process to form an envelope around the caspid. Following viral
replication the new viruses then go on to infect new hosts.
Most of the time body’s immune
system is capable enough to get rid of viruses. Problem arises when the virus
attacks the immune system to gain access to a cell and takes control over it .
These are the ones capable of causing outbreaks and sometimes pandemics.
Viruses are microscopic parasites, generally much smaller than
bacteria.They lack the capacity to thrive and reproduce outside of a host
body. |
When a virus is completely assembled and capable of infection, it is
known as a virion. According to the authors of “Medical Microbiology 4th Ed.”
(University of Texas Medical Branch at Galveston, 1996), the structure of a
simple virion comprises of an inner nucleic acid core surrounded by an outer
casing of proteins known as the capsid. Capsids protect viral nucleic acids
from being chewed up and destroyed by special host cell enzymes called
nucleases. Some viruses have a second protective layer known as the envelope.
This layer is usually derived from the cell membrane of a host; little stolen
bits that are modified and repurposed for the virus to use.
The DNA or RNA found in the core of the
virus can be single stranded or double stranded. It constitutes the genome or the sum
total of a virus’s genetic information. Viral genomes are generally small in
size, coding only for essential proteins such as capsid proteins, enzymes, and
proteins necessary for replication within a host cell.
The
primary role of the virus or virion is to “deliver its DNA or RNA genome into
the host cell so that the genome can be expressed (transcribed and translated)
by the host cell,” according to "Medical Microbiology."
First, viruses need to access the inside of
a host’s body. Respiratory passages and open wounds can act as gateways for
viruses. Sometimes insects provide the mode of entry. Certain viruses will
hitch a ride in an insect’s saliva and enter the host’s body after the insect
bites. According to the authors of “Molecular Biology of the Cell, 4th Ed”
(Garland Science, 2002) such viruses can replicate inside both insect and host
cells, ensuring a smooth transition from one to the other. Examples include the
viruses that cause yellow fever and dengue fever.
Viruses
will then attach themselves to host cell surfaces. They do so by recognizing
and binding to cell surface receptors, like two interlocking puzzle pieces.
Many different viruses can bind to the same receptor and a single virus can
bind different cell surface receptors. While viruses use them to their
advantage, cell surface receptors are actually designed to serve the
cell.
After a virus binds to the surface of the
host cell, it can start to move across the outer covering or membrane of the
host cell. There are many different
modes of entry. HIV, a virus with an envelope, fuses with the
membrane and is pushed through. Another enveloped virus, the influenza virus,
is engulfed by the cell. Some non-enveloped viruses, such as the polio virus,
create a porous channel of entry and burrow through the membrane.
Once
inside, viruses release their genomes and also disrupt or hijack various parts
of the cellular machinery. Viral genomes direct host cells to ultimately
produce viral proteins (many a time halting the synthesis of any RNA and
proteins that the host cell can use). Ultimately, viruses stack the deck in
their favor, both inside the host cell and within the host itself by creating
conditions that allow for them to spread. For example, when suffering from the
common cold, one sneeze emits 20,000 droplets containing rhinovirus or
coronavirus particles, according to "Molecular Biology of the Cell."
Touching or breathing those droplets in, is all it takes for a cold to spread.
The recent emergence of the novel coronavirus behind the COVID-19 pandemic throws a spotlight on the risks animals can pose to humans as the source of new viruses. The virus in question, known as SARS-CoV-2, was linked to a “wet market” for wild animal trade in Wuhan, China, although it’s by no means certain this was the source of the human version of the virus. Bats were identified as the animal with the closest known equivalent virus although, again, we’re not sure that a bat provided the direct origin of SARS-CoV-2.
So how do new viruses
actually emerge from the environment and start infecting humans? Every virus
has a unique origin in terms of its timing and mechanism, but there are some
general facts that are true for all species of emerging virus.
The first thing to
know is that it is rare for viruses to jump between species. In order for a
virus to successfully jump into a
new species of host, it must be able to do several things.
First, it must be
able to establish an infection in the new host by replicating itself there.
This is not a given, as many viruses can only infect specific types of cells,
such as lung cells or kidney cells. When attacking a cell, a virus binds to
specific receptor molecules on the cell’s surface and so may not be able to
bind to other types of cell. Or the virus may simply be unable to replicate
inside the cell for whatever reason.
Once it has infected
a new host, the virus must also be able to replicate itself enough to infect
others and transmit itself to them. This, again, is very rare and most virus
jumps will result in what we call “dead-end hosts” from which the virus cannot
transmit itself and eventually dies.
For example, the
influenza virus H5N1, or ‘bird flu’ can infect humans from
birds, but has very limited transmission between humans. Occasionally, this
barrier is overcome, and the emerging virus is able to jump to a new host,
establishing a new transmission chain and a novel outbreak.
From research over the past few decades, we understand some of the
mechanisms that contribute to virus jumps between species. Influenza virus is a
classic example. The virus contains eight genome segments and if two different
viruses infect the same cell, segments from both can mix to create a novel
virus species. If the proteins on the surface of the new virus have
significantly changed from currently circulating influenza virus strains, then
no one will have immunity and the new virus can easily spread.
This shift in the influenza virus is called antigenic
shift. This is what we think
happened with the 2009 H1N1 influenza epidemic, with the shift
occurring in pigs and then jumping to humans to start the outbreak. There is
also genetic evidence that this mechanism can
occur in coronaviruses, although its role in the emergence of SARS-CoV-2
remains to be determined.
New viruses can also emerge through genetic mutations
within the virus genome, which are more common among viruses that, instead of
deoxyribonucleic acid (DNA), store their genetic information in the similar
molecule Ribonucleic acid (RNA). This is because these viruses (with the
exception of coronaviruses) lack a way to check for mistakes when they
replicate. Most of the mutations produced during replication will be damaging
to the virus but some will enable it to infect a new host more effectively.
New coronavirus
So what do we think happened in the case of SARS-CoV-2?
Recent analysis of the genome suggest that the virus had been circulating in a
very similar form to today for approximately 40 years. The closest relative of
the virus that we can identify is one found in bats. However, this virus and
SARS-CoV-2 probably shared a common ancestor approximately 40-70 years ago, and
so this bat virus is not the cause of the outbreak.
Although these viruses share a common ancestor, 40 years
of evolution since then has separated them. This means that SARS-CoV-2 may have
jumped to humans from bats, or it may have come via an intermediate species.
Closely related viruses have been found in pangolins, for example. But the exact
path of the genetically distinct SARS-CoV-2 will remain a mystery until we are
able to find closer relative species in the environment.
It is also unclear what changed in the virus to allow it
to infect humans so easily. However, given that three major diseases have
emerged from the coronavirus family in the last 20 years – Severe acute
respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and
COVID-19 – it is likely that this will not be the last time a coronavirus jumps
into humans and causes a new disease outbreak.
What makes this more likely is that while they circulate
in all animals in the world, viruses are only able to jump to humans when they
have an opportunity from contact between us and other animals. Humans have always come
into contact with new viruses as they have explored new areas and spread across
the globe. But increased human activity in wild areas and the trade in wild
animals creates a perfect breeding ground.
This is also compounded by our global connectedness, which enables
a new disease to spread around the world in days. We
must accept some responsibility for these emergence events as we continue to
disturb natural environments and increase the likelihood of viruses jumping
into humans.
The fact that the host range — the group of
cell types that a virus can
infect — is generally restricted serves as a basis for classifying viruses. A
virus that infects only bacteria is called a bacteriophage,
or simply a phage.
Viruses that infect animal or plant cells are referred to generally
as animal viruses or plant viruses. A few viruses can
grow in both plants and the insects that feed on them. The highly mobile
insects serve as vectors for transferring such viruses between susceptible
plant hosts. An example is potato yellow dwarf virus, which can grow in
leafhoppers (insects that feed on potato plant leaves) as well as in potato
plants. Wide host ranges are characteristic of some strictly animal viruses,
such as vesicular stomatitis virus, which grows in insects and in many
different types of mammalian cells. Most animal viruses, however, do not
cross phyla, and some (e.g., poliovirus) infect only closely related species
such as primates. The host-cell range of some animal viruses is further
restricted to a limited number of cell types because only these cells have
appropriate surface receptors to which the virions can attach. |
Sunday, 13 December 2020
Making of Human
Development
of the human body is the process of growth to maturity. The process begins
with fertilization,
where an egg released from the ovary of
a female is penetrated by a sperm
cell from a male. The resulting zygote develops
through mitosis and cell
differentiation, and the resulting embryo then implants in
the uterus,
where the embryo continues development through a fetal stage until birth.
Germinal Stage
The germinal stage refers to the time from fertilization through the development of the early embryo until implantation is completed in the uterus. The germinal stage takes around 10 days. During this stage, the zygote begins to divide, in a process called cleavage. A blastocyst is then formed and implanted in the uterus. Embryonic development continues with the next stage of gastrulation, when the three germ layers of the embryo form in a process called histogenesis, and the processes of neurulation and organogenesis follow.
Blastocyst Development
Blastocyst development is important stage
for the formation of organs in embryo.
The
blastocyst stays inside a protective cover during maturation called zona
pellucida, which could be described as an egg shell. The outer cells are
located right below this cover, which will create the future placenta and
surrounding tissues to support fetal development in the uterus. The inner cells
of the blastocyst will become the different tissues and organs of the human
body, such as bones, muscles, skin, liver, and heart.
Embryo
Development
As the blastocyst reaches the final steps
in the implantation process into the inner lining of the uterus, it evolves
into a structure called an embryo. This is the time when internal organs and
external structures develop. The mouth, lower jaw, throat are emerging, while
the blood circulation system starts its evolution and a heart tube is created.
The ears arise and arms, legs, fingers, toes, and eyes are being shaped. The
brain and the spinal cord are already formed, while the digestive tract and
sensory organs start their development. The first bones are replacing the
cartilage.
After ten-twelve weeks of pregnancy, the
embryo moves into the final stage of development, a fetus.
Gastrulation
Gastrulation starts in the 3rd week, the inner cell or
embryo starts differentiating into three germinal layers, i.e. ectoderm,
endoderm and mesoderm. These cells transform and get differentiated to all the
tissues and organs, like nerve, blood, muscle, bone, digestive tract, etc.
Ectoderm- nervous system,
brain, spinal cord, epidermis, hair, nails, etc.
Mesoderm- connective tissue,
muscles, circulatory system, notochord, bone, kidney, gonads
Endoderm- internal organs,
stomach, liver, pancreas, bladder, lung, gut lining
Fetal Development
By the twelfth
week of fertilization the embryo moves into the final stage of development
called the fetal stage. By now, the fetus has formed all of the organs and
structures necessary for a baby, but those organs still need to grow and
develop.
At three months of
pregnancy, the upper and lower extremities of the fetus are completely
developed. Ears and teeth are formed and the reproductive organs have evolved.
At the end of this month, the fetus has completed the expansion of most of the
circulatory and urinary systems and its length is about 5 inches.
At six months, the
fetus can respond to sounds and is around 12 inches long. The fetus continues
to develop and grow changing position and responding to sounds, and stimuli.
The length of the little body can reach 14 inches.
The fetus becomes
a baby at month eight. The brain is evolving quickly so the baby can see and
hear, although the respiratory system requires maturation. The baby can weigh
approximately 5 pounds. Close to the end of the pregnancy at month 9, the baby
responds to stimuli, can move the whole body but space around the new human
being is becoming too tight.
PLACENTA
The interdigitated chronic
villi of trophoblast and uterine cells form the placenta, which is the
connection between the mother and the growing foetus.
The placenta provides
nourishment and oxygen to the embryo and helps in removing carbon dioxide and
waste produced by the embryo. It also acts as an endocrine gland and secretes
various hormones like hCG (Human Chorionic Gonadotropin), estrogen, progestogens,
etc. for maintenance of pregnancy.
Formation of Human Organ
1.The heart is
the first functional organ to develop and starts to beat and pump blood at
around 22 days.
2.The digestive system starts to develop
from the third week and by the twelfth week, the organs have correctly
positioned themselves.
3. The
respiratory system develops from the lung bud, which appears in
the ventral wall of the foregut about four weeks into development.
4. Brain developed around eight week
5. After12 week Male and female external
genital differences observable
Stages of Growth Month-by-Month in Pregnancy
First trimester
The first trimester will span from conception to 12 weeks. This
is generally the first three months of pregnancy. During this trimester, your
baby will change from a small grouping of cells to a fetus that is starting to
have a baby’s features.
Second trimester
This middle section of pregnancy is often thought of as the best
part of the experience. By this time, any morning sickness is probably gone and
the discomfort of early pregnancy has faded. The baby will start to develop
facial features during this month. You may also start to feel movement as your
baby flips and turns in the uterus. During this trimester, many people find out
the sex of the baby. This is typically done during an anatomy scan (an
ultrasound that checks your baby’s physical development) around 20 weeks.
Third trimester
This is the final part of your pregnancy. You may be tempted to
start the countdown till your due date and hope that it would come early, but
each week of this final stage of development helps your baby prepare for
childbirth. Throughout the third trimester, your baby will gain weight quickly,
adding body fat that will help after birth.
Tuesday, 8 December 2020
Know The Making of Man and Woman
Child is a Father of man but which decides whether
child becomes man or woman.We are
providing here some interesting
facts about how biological activities
determine the fetus future.
The normal human fetus of
either sex has the potential to develop either male or female organs, depending
on genetic and hormonal influences
Every fetus contains structures that are capable of developing into either male or female genitalia, and, regardless of the complement of sex chromosomes, all developing embryos become feminized unless masculinizing influences come into play at key times during gestation.
Most mammals, including humans, have an XY sex-determination system: the Y chromosome carries factors responsible for triggering male development. In the absence of a Y chromosome, the fetus will undergo female development. This is because of the presence of the sex-determining region of the Y chromosome, also known as the SRY gene. Thus, male mammals typically have
an X and a Y chromosome (XY), while female mammals typically have two X chromosomes (XX).
In humans, biological sex is determined by five factors present at birth: the
presence or absence of a Y chromosome, the type of gonads, the sex hormones,
the internal genitalia (such as the uterus in
females), and the external genitalia.
Chromosomal sex is determined at the time
of fertilization; a chromosome from
the sperm cell, either X or Y,
fuses with the X chromosome in the egg cell. Gonadal sex refers to
the gonads, that is the testis or ovaries, depending on which genes are
expressed. Phenotypic sex refers to the structures of the external and
internal genitalia.
A human fetus does not
develop its external sexual organs until seven weeks after fertilization. The
fetus appears to be sexually indifferent, looking neither like a male or a
female. Over the next five weeks, the fetus begins producing hormones that
cause its sex organs to grow into either male or female organs. This process is
called sexual differentiation.
As we know In humans, each egg contains 23 chromosomes, of which 22 are autosomes and 1 is
a female sex chromosome (the X chromosome). Each sperm also contains 23 chromosomes:
22 autosomes and either one female sex chromosome male sex chromosome (or one the Y chromosome).
Two precursor organs
exist in the fetus: the Wolffian duct,
which differentiates into
the structures of the male genital tract, and the Müllerian
duct, the source of the female reproductive organs. During the third
month of fetal development, the Sertoli cells of the testes of XY fetuses begin
to secrete a substance called Müllerian inhibiting hormone.
This causes the Müllerian ducts to atrophy instead of develop into the oviducts
(fallopian tubes)
and uterus. In
addition, the Wolffian ducts are stimulated by testosterone to eventually develop into the
spermatic ducts (ductus
deferens), ejaculatory ducts, and seminal vesicles. If the
fetal gonads do not secrete testosterone at the proper time, the genitalia
develop in the female direction
Males become externally distinct
between 8 and 12 weeks, as androgens enlarge the phallus and cause the
urogenital groove and sinus to fuse in the midline, producing an
unambiguous penis with
a phallic urethra, and a thinned, rugated scrotum.
Dihydrotestosterone will differentiate the remaining male characteristics of
the external genitalia.
A sufficient amount of any androgen
can cause external masculinization. The most potent is dihydrotestosterone (DHT), generated from
testosterone in skin and genital tissue by the action of 5α-reductase. A male
fetus may be incompletely masculinized if this enzyme is deficient.
Wednesday, 2 December 2020
Facts About Vaccine
Facts About Vaccine
We are hearing these days that there is only solution to the
Corona pandemic is vaccination.Here we
are trying to through some light on what is vaccine,history,its stage of development,and types.
A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease.[1] A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future. Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight a disease that has already occurred, such as cancer).Edward Jenner hs developed the first vaccine Variolae vaccine (smallpox of the cow) known as the cowpox.His method underwent medical and technological changes over the next 200 years, and eventually resulted in the eradication of smallpox.
Louis Pasteur’s 1885 rabies vaccine was the
next to make an impact on human disease. And then, at the dawn of bacteriology,
developments rapidly followed. Antitoxins and vaccines against diphtheria,
tetanus, anthrax, cholera, plague, typhoid, tuberculosis, and more were
developed through the 1930s.
The middle of the 20th century was an
active time for vaccine research and development. Methods for growing viruses
in the laboratory led to rapid discoveries and innovations, including the
creation of vaccines for polio. Researchers targeted other common childhood
diseases such as measles, mumps, and rubella, and vaccines for these diseases
reduced the disease burden greatly.
Innovative techniques now drive vaccine
research, with recombinant DNA technology and new delivery techniques leading
scientists in new directions. Disease targets have expanded, and some vaccine
research is beginning to focus on non-infectious conditions such as addiction
and allergies.
Different
Types of Vaccines
Vaccines are made using several different processes. They may contain live viruses that have been attenuated (weakened or altered so as not to cause illness); inactivated or killed organisms or viruses; inactivated toxins (for bacterial diseases where toxins generated by the bacteria, and not the bacteria themselves, cause illness); or merely segments of the pathogen (this includes both subunit and conjugate vaccines).
Inactivated
Some vaccines contain inactivated, but
previously virulent, micro-organisms that have been destroyed with chemicals,
heat, or radiation.Examples include the IPV polio vaccine, hepatitis A vaccine, rabies vaccine and most influenza vaccines.
Attenuated
Some vaccines contain live, attenuated microorganisms.
Many of these are active viruses that have
been cultivated under conditions that disable their virulent properties, or
that use closely related but less dangerous organisms to produce a broad immune
response. Although most attenuated vaccines are viral, some are bacterial in
nature. Examples include the viral diseases yellow fever, measles, mumps, and rubella, and the bacterial
disease typhoid. The live Mycobacterium tuberculosis vaccine
developed by Calmette and Guérin is not made of a contagious strain
but contains a virulently modified strain called "BCG"
used to elicit an immune response to the vaccine. The live attenuated vaccine
containing strain Yersinia
pestis EV is used for plague immunization. Attenuated vaccines
have some advantages and disadvantages. Attenuated, or live, weakened, vaccines
typically provoke more durable immunological responses. But they may not be
safe for use in immunocompromised individuals, and on rare occasions mutate to
a virulent form and cause disease.
Toxoid
Toxoid vaccines are made from
inactivated toxic compounds that cause illness rather than the micro-organism. Examples
of toxoid-based vaccines include tetanus and diphtheria. Toxoid vaccines are known for
their efficacy. Not all toxoids are for micro-organisms; for
example, Crotalus
atrox toxoid is used to vaccinate dogs against rattlesnake bites.
Subunit
Rather than introducing an inactivated
or attenuated micro-organism to an immune system (which would constitute a
"whole-agent" vaccine), a subunit vaccine uses a fragment of it
to create an immune response. Examples include the subunit vaccine
against hepatitis B virus that
is composed of only the surface proteins of the virus (previously extracted
from the blood serum of
chronically infected patients, but now produced by recombination of the viral genes
into yeast) or as an edible algae vaccine,
the virus-like particle (VLP)
vaccine against human papillomavirus (HPV)
that is composed of the viral major capsid protein, and the hemagglutinin and neuraminidase subunits of the influenza virus. A subunit
vaccine is being used for plague immunization.
Conjugate
Certain bacteria have polysaccharide outer coats that are
poorly immunogenic.
By linking these outer coats to proteins (e.g., toxins), the immune system can be led to recognize
the polysaccharide as if it were a protein antigen. This approach is used in
the Haemophilus influenzae type B vaccine.
Heterotypic
Also known as heterologous or "Jennerian" vaccines, these are vaccines that are pathogens of other animals that either do not cause disease or cause mild disease in the organism being treated. The classic example is Jenner's use of cowpox to protect against smallpox. A current example is the use of BCG vaccine made from Mycobacterium bovis to protect against human tuberculosis.
A number of innovative vaccines are also
in development and in use:
·
Dendritic cell vaccines combine dendritic cells with
antigens in order to present the antigens to the body's white blood cells, thus
stimulating an immune reaction. These vaccines have shown some positive preliminary
results for treating brain tumors and are also tested in malignant
melanoma.
·
DNA vaccination –
The proposed mechanism is the insertion and expression of
viral or bacterial DNA in human or animal cells (enhanced by the use of electroporation),
triggering immune system recognition. Some cells of the immune system that
recognize the proteins expressed will mount an attack against these proteins
and cells expressing them. Because these cells live for a very long time, if
the pathogen that
normally expresses these proteins is encountered at a later time, they will be
attacked instantly by the immune system. One potential advantage of DNA
vaccines is that they are very easy to produce and store.
·
Recombinant vector –
by combining the physiology of one micro-organism and the DNA of another, immunity can be
created against diseases that have complex infection processes. An example is
the RVSV-ZEBOV vaccine licensed to Merck that is being used
in 2018 to combat ebola in Congo.
·
RNA vaccine is
a novel type of vaccine which is composed of the nucleic acid RNA, packaged
within a vector such as lipid nanoparticles. A number of RNA vaccines are under
development to combat the COVID-19 pandemic.
·
T-cell receptor peptide
vaccines are under development for several diseases using models of Valley Fever, stomatitis,
and atopic dermatitis. These peptides have been shown to
modulate cytokine production
and improve cell-mediated immunity.
·
Targeting of identified bacterial proteins
that are involved in complement inhibition would neutralize the key bacterial
virulence mechanism.[50]
·
The use of plasmids has
been validated in preclinical studies as a protective vaccine strategy for
cancer and infectious diseases. However, in human studies, this approach has
failed to provide clinically relevant benefit. The overall efficacy of plasmid
DNA immunization depends on increasing the plasmid's immunogenicity while
also correcting for factors involved in the specific activation of immune
effector cells.
While most vaccines are created using
inactivated or attenuated compounds from micro-organisms, synthetic vaccines are composed
mainly or wholly of synthetic peptides, carbohydrates, or antigens.
Valence
Vaccines may be monovalent (also
called univalent) or multivalent (also called polyvalent).
A monovalent vaccine is designed to immunize against a single antigen or single
microorganism. A multivalent or polyvalent vaccine is designed to immunize
against two or more strains of the same microorganism, or against two or more
microorganisms. The valency of a multivalent vaccine may be denoted with a
Greek or Latin prefix (e.g., tetravalent or quadrivalent). In
certain cases, a monovalent vaccine may be preferable for rapidly developing a
strong immune response.
When two or more vaccines are mixed
together in the same formulation, the two vaccines can interfere. This most
frequently occurs with live attenuated vaccines, where one of the vaccine
components is more robust than the others and suppresses the growth and immune
response to the other components. This phenomenon was first noted in the
trivalent Sabin polio vaccine,
where the amount of serotype 2 virus in the vaccine had to be reduced to stop
it from interfering with the "take" of the serotype 1 and 3 viruses
in the vaccine. This phenomenon has also been found to be a problem with
the dengue vaccines currently being
researched.
Stages of
Vaccine Development and Testing
Vaccine
development and testing follow a standard set of steps. The first stages are
exploratory in nature. Regulation and oversight increase as the candidate
vaccine makes its way through the process.
Exploratory Stage
This stage involves basic laboratory research and often lasts 2-4 years.
Federally funded academic and governmental scientists identify natural or
synthetic antigens that might help prevent or treat a disease. These antigens could include
virus-like particles, weakened viruses or bacteria, weakened bacterial toxins,
or other substances derived from pathogens.
Pre-Clinical
Stage
Pre-clinical
studies use tissue-culture or cell-culture systems and animal testing to assess
the safety of the candidate vaccine and its immunogenicity, or ability to
provoke an immune response. Animal subjects may include mice and monkeys. These
studies give researchers an idea of the cellular responses they might expect in
humans. They may also suggest a safe starting dose for the next phase of research
as well as a safe method of administering the vaccine.
Researchers
may adapt the candidate vaccine during the pre-clinical state to try to make it
more effective. They may also do challenge studies with the animals, meaning
that they vaccinate the animals and then try to infect them with the target
pathogen.
Many candidate vaccines never progress beyond this stage because they fail to produce the desired immune response. The pre-clinical stages often lasts 1-2 years and usually involves researchers in private industry.
Next
Steps: Clinical Studies with Human Subjects
Phase
I Vaccine Trials
This
first attempt to assess the candidate vaccine in humans involves a small group
of adults, usually between 20-80 subjects. If the vaccine is intended for
children, researchers will first test adults, and then gradually step down the
age of the test subjects until they reach their target. Phase I trials may be
non-blinded (also known as open-label in that the researchers and perhaps
subjects know whether a vaccine or placebo is used).
The
goals of Phase 1 testing are to assess the safety of the candidate vaccine and
to determine the type and extent of immune response that the vaccine provokes.
In a small minority of Phase 1 vaccine trials, researchers may use the challenge
model, attempting to infect participants with the pathogen after the
experimental group has been vaccinated. The participants in these studies are
carefully monitored and conditions are carefully controlled. In some cases, an
attenuated, or modified, version of the pathogen is used for the challenge.
A
promising Phase 1 trial will progress to the next stage.
Phase
II Vaccine Trials
A
larger group of several hundred individuals participates in Phase II testing.
Some of the individuals may belong to groups at risk of acquiring the disease.
These trials are randomized and well controlled, and include a placebo group.
The
goals of Phase II testing are to study the candidate vaccine’s safety,
immunogenicity, proposed doses, schedule of immunizations, and method of
delivery.
Phase
III Vaccine Trials
Successful
Phase II candidate vaccines move on to larger trials, involving thousands to
tens of thousands of people. These Phase III tests are randomized and double
blind and involve the experimental vaccine being tested against a placebo (the
placebo may be a saline solution, a vaccine for another disease, or some other
substance).
One Phase III goal is to assess vaccine safety in a large group of people. Certain rare side effects might not surface in the smaller groups of subjects tested in earlier phases.
Vaccine
efficacy is tested as well. These factors might include 1) Does the candidate
vaccine prevent disease? 2) Does it prevent infection with the pathogen? 3)
Does it lead to production of antibodies or other types of immune responses
related to the pathogen?
visit us www.madadapp.com